Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Closure of the Company's Offer under the Albion VCTs Prospectus Top Up Offers 2018/19

5 Mar 2019 10:50



Closure of the Company's Offer under the Albion VCTs Prospectus Top Up Offers 2018/19

Albion Venture Capital Trust PLC

LEI Code 213800JKELS32V2OK421

CLOSURE OF THE COMPANY'S OFFER UNDER THE ALBION VCTS PROSPECTUS TOP UP OFFERS 2018/19 ("Albion VCT Offers")

The Board of Albion Venture Capital Trust PLC (the "Company") is pleased to announce that it has reached its £8 million limit under its offer for subscription pursuant to the prospectus dated 7 January 2019 ("Offer"), which is now fully subscribed and has closed to further applications for subscription.

Allotments in respect of valid applications received prior to the Offer closing to further applications are expected to take place on 1 April 2019, for applications in respect of the current tax year, and on 12 April 2019 for applications in respect of the 2019/2020 tax year. Dealing in such shares will commence within 3 business days following allotment.

The offers in respect of the remaining five companies participating in the Albion VCT Offers remain open and valid applications for shares in the Company received subsequent to the Offer closing will be dealt with in accordance with prospective investors' instructions on their application forms.

5 March 2019

Enquiries:

Will Fraser-AllenDeputy Managing Partner, Albion Capital Group LLPTel: 0207 601 1850


Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.